Endocrinology Vol. 140, No. 1 358-364
Copyright © 1999 by The Endocrine Society
Transcriptional Activation of Gonadotropin-Releasing Hormone (GnRH) Receptor Gene by GnRH: Involvement of Multiple Signal Transduction Pathways1
Xinwei Lin and
P. Michael Conn
Oregon Regional Primate Research Center (X.L., P.M.C.), Beaverton,
Oregon 97006; and the Department of Physiology and Pharmacology, Oregon
Health Sciences University (P.M.C.), Portland, Oregon 97201
Address all correspondence and requests for reprints to: Dr. P. Michael Conn, Oregon Regional Primate Research Center, 505 NW 185th Avenue, Beaverton, Oregon 97006. E-mail: connm{at}ohsu.edu
 |
Abstract
|
|---|
Previous studies have shown that GnRH activates transcriptional
activity of its own receptor (GnRHR) gene in part through the cAMP
signal transduction pathway. In the present study we explored the
possible involvement of multiple signal transduction pathways in GnRH
regulation of GnRHR gene transcription; these studies relied upon a
luciferase reporter gene vector (GnRHR-pXP2) containing a 1226-bp
promoter fragment (-1164 to +62, relative to the major transcription
start site) of the mouse GnRHR gene in GGH3 cells
(GH3 cells stably expressing rat GnRHR). Activation of
protein kinase C (PKC) by phorbol myristic acid significantly
stimulated GnRHR-luciferase reporter gene (GnRHR-Luc) activity, but did
not potentiate the stimulation of GnRHR-Luc activity by the GnRH
agonist, buserelin (GnRH-A). Inhibition of PKC by PKC inhibitor (GF
109203X) or depletion of PKC blocked phorbol myristic acid- or
GnRH-A-stimulated GnRHR-Luc activity, but did not affect
(Bu)2cAMP-stimulated GnRHR-Luc activity. In
addition, GnRH-A-stimulated GnRHR-Luc activity was inhibited by
preventing external Ca2+ influx with the external
Ca2+ chelator EGTA or the Ca2+ ion channel
antagonist, D600. Surprisingly, overexpression of the mitogen-activated
protein kinase (MAPK) kinase kinase (Raf-1) inhibited GnRHR-Luc
activity and partially blocked GnRH-A-stimulated GnRHR-Luc activity. In
contrast, inhibition of MAPK activity by MAPK kinase inhibitor (PD
98059) or by overexpression of kinase-deficient MAPKs activated basal
and GnRH-A-stimulated GnRHR-Luc activity. These results suggested that
PKC- and Ca2+-dependent signal transduction pathways
participate in the GnRH activation of GnRHR promoter activity, and that
the MAPK cascade is involved in the negative regulation of basal and
GnRH-stimulated GnRHR transcriptional activity conferred by the 1226-bp
promoter fragment.
 |
Introduction
|
|---|
GnRH STIMULATES the synthesis and release
of pituitary gonadotropins (LH and FSH), acting through the GnRH
receptor (GnRHR) on the plasma membrane (1). The GnRHR is a member of
the G protein-coupled receptor (GPCR) family (2). The GnRHR couples to
multiple G proteins, including Gq/11, which activates
phospholipase C, leading to production of diacylglycerol and activation
of protein kinase C (PKC) (3, 4, 5, 6, 7). Activation of GnRHR also stimulates
Ca2+ influx and an increase in the intracellular
Ca2+ concentration (7) as well as an increase in cAMP
levels (8, 9), suggesting that multiple signal transduction pathways
may mediate GnRH action.
Rat pituitary GGH3 cells, a GH3-derived cell
line (10) stably expressing rat GnRHR (11), is a useful model system
for study of GnRH action (12). GGH3 cells transfected with
regulatory regions of the LH or FSH subunit genes fused to a luciferase
reporter gene respond to GnRH with an increase in promoter activity
comparable to that seen in primary rat pituitary cells (13). In
GGH3 cells, the GnRHR is coupled to Gq/11 as
well as to Gs, which activates adenylate cyclase, leading
to production of cAMP and activation of protein kinase A (PKA) (12, 14, 15, 16). A recent study relying on palmitoylation of G proteins and
overexpression of G protein
-subunit complementary DNAs (cDNAs)
showed that the GnRHR was able to couple to Gq/11 as well
as to Gs and Gi in pituitary gonadotropes and
GGH3 cells (17), suggesting that similar signal
transduction pathways are employed to mediate GnRH action in
GGH3 cells and pituitary cells.
Mitogen-activated protein kinase (MAPK), also designated extracellular
signal-regulated kinases (ERKs), comprise a family of serine/threonine
kinases that are involved in the transduction of externally derived
signals regulating cell growth, division, and differentiation (18).
Upon activation, MAPKs translocate to the nucleus, where they
phosphorylate and activate nuclear transcription factors involved in
DNA synthesis and cell division (18, 19, 20). MAPK was identified in
primary pituitary cells as well as in pituitary-derived cell lines,
including GH3 and
T31 cells (21, 22, 23). GnRH was shown
to activate MAPK activity, probably through the PKC pathway (22, 23, 24, 25, 26).
GnRH also activates the MAPK cascade, which, in turn, contributes to
stimulation of gonadotropin
-subunit gene promoter activity
(25, 26, 27). Recent studies revealed that GnRH regulates transcriptional
activities of LH and FSH subunits in part through differential use of
PKC and Ca2+ pathways (28) or PKC/MAPK and Ca2+
signal transduction pathways (27).
Several studies showed that pituitary GnRHR number (7) and the levels
of GnRHR messenger RNA (29, 30) change during the estrous cycle and are
associated with changes in the sensitivity of gonadotropes to GnRH and
levels of serum gonadotropins, suggesting that GnRHR is an important
site for the regulation of gonadotropin release, and GnRH is involved
in the regulation of its own receptor (7). In addition, our previous
study using GGH3 cells showed that GnRH activates
transcriptional activity of its own receptor gene in part through the
cAMP signal transduction pathway (31). In the present study we explored
the possibility of involvement of multiple signal transduction pathways
in regulation of GnRHR gene transcription by GnRH in the
GGH3 cell line.
 |
Materials and Methods
|
|---|
Materials
Natural sequence GnRH was provided by the National Pituitary
Agency. A GnRH agonist (GnRH-A), buserelin
(D-tert-butyl-Ser6-des-Gly10-Pro9-ethylamide-GnRH),
was a gift from Hoechst-Roussel Pharmaceuticals (Somerville, NJ).
(Bu)2cAMP (Sigma Chemical Co., St.
Louis, MO), phorbol 12-myristate 13-acetate (PMA; Sigma Chemical Co.), EGTA (Sigma Chemical Co.), PD 98059
(2'-amino-3'-methoxyflavone; Calbiochem, La Jolla, CA), GF
109203X (bisindolylmaleimide I; Calbiochem), and D600
(methoxyverapamil; Knoll, Whippany, NJ) were obtained from the sources
indicated. DMEM, OPTI-MEM, and lipofectamine were purchased from
Life Technologies (Grand Island, NY). Restriction enzymes,
modified enzymes, and competent cells for subcloning were purchased
from Promega Corp. (Madison, WI). Other reagents were of
the highest degree of purity available from commercial sources.
Reporter plasmids and expression vectors
Luciferase reporter gene vector (GnRHR-pXP2) with a 1226-bp
promoter fragment (-1164 to +62 relative to the major transcription
start site) of the mouse GnRHR (mGnRHR) gene (32) was provided by Dr.
W. W. Chin. Promoterless pXP2 vector was generated by digestion of
the GnRHR-pXP2 construct with BamHI and BglII to
delete the GnRHR gene fragment and religation of the vector. An
expression vector (pCIS-lacZ) expressing ß-galactosidase
driven by the cytomegalovirus promoter was provided by Dr. Tae H. Ji
and used as an internal control (33). Expression vectors for
kinase-deficient forms of human ERK1 (pCEP4L/Erk1 K71R, ERK1-Mut) and
ERK2 (pCEP4L/Erk2 K52R, ERK2-Mut) were provided by Dr. Melanie Cobb
(34, 35). An expression vector for wild-type human Raf-1 (pUSE Raf-1)
(36) was obtained from Upstate Biotechnology, Inc. (Lake Placid, NY),
and an empty expression vector, pcDNA3.1, was obtained from
Invitrogen (Carlsbad, CA) and used as a control
plasmid.
Transient transfection of GGH3 cells
GnRHR-pXP2 reporter gene vector or control vector pXP2 was
transiently expressed in GGH3 cells (GGH3-1'
line) (11). GGH3 cells were maintained in growth medium
[DMEM containing 10% FCS (HyClone Laboratories, Inc.,
Logan, UT) and 20 µg/ml gentamicin (Gemini Bioproducts, Calabasas,
CA)] in a humidified atmosphere (37 C) containing 5% CO2.
Cells (5 x 105/well) were seeded in six-well plates
(Costar, Cambridge, MA). Twenty-four hours after plating,
the cells were transfected with 1.5 µg GnRHR-pXP2 or promoterless
pXP2 plus 0.5 µg pCIS-lacZ/well using 5 µl lipofectamine
in 1 ml OPTI-MEM. Five hours later, 1 ml DMEM containing 20% FCS was
added to each well. Twenty-four hours after the start of transfection,
the medium was replaced with fresh growth medium, and the cells were
allowed to grow for another 24 h before treatment and functional
assays (luciferase assay and ß-galactosidase assay). For transfection
of kinase-defective expression vectors, GGH3 cells were
transfected with 1.5 µg GnRHR-pXP2 or promoterless pXP2 plus 1 µg
ERK1-Mut, 1 µg ERK2-Mut, or 0.5 µg ERK1-Mut plus 0.5 µg
ERK2-Mut/well. An equal amount (1 µg) of empty expression vector
pcDNA3.1 was used in the control transfection. For transfection of
Raf-1 expression vector, GGH3 cells were transfected with
1.5 µg GnRHR-pXP2 or promoterless pXP2 plus different amounts (0,
0.2, 1, or 5 µg) of Raf-1 vector per well. The total amount of
expression vector was maintained at a constant value (6.5 µg) for
each transfection by adding appropriate amounts of empty expression
vector (pcDNA3.1). pCIS-lacZ (0.5 µg/well) was used as an
internal control.
Luciferase and ß-galactosidase assays
After treatment of GGH3 cells with GnRH-A or other
compounds for the indicated times, cells were washed twice with PBS and
lysed in 150 µl reporter lysis buffer (Promega Corp.).
Luciferase activity in 20 µl cell lysate was determined using the
luciferase assay system (Promega Corp.) in a LuciCount
microplate luminometer (Packard, Meriden, CT). ß-Galactosidase
activity in 30 µl cell lysate was also measured using a
ß-galactosidase enzyme assay system (Promega Corp.) in a
SpectraCount photometric microplate counter (Packard) and was used as
an internal control. The luciferase activity was normalized for the
transfection efficiency of each well by dividing luciferase activity by
ß-galactosidase activity.
Data analysis
Transfections were performed in triplicate for each experiment.
The data shown are the means of triplicate wells for the same treatment
in each experiment and are presented as the mean ±
SEM of replicates (n = 3) in each experiment. The
SEM was typically less than 10% of the mean. The data were
analyzed by one-way ANOVA followed by Duncans multiple range test.
P < 0.05 was considered significant. Each experiment
was repeated at least three times with similar results.
 |
Results
|
|---|
Involvement of the PKC pathway in GnRH activation of GnRHR gene
transcriptional activity
The transcriptional activity of the GnRHR promoter in the
transiently transfected GGH3 cells was assessed by
expression of the GnRHR promoter-controlled reporter gene (luciferase
gene). Transient transfection of GGH3 cells with
GnRHR-pXP2, a luciferase reporter gene vector containing a 1226-bp
promoter fragment (-1164 to +62, relative to the major transcription
start site) of the mGnRHR gene, resulted in a 10- to 25-fold increase
in GnRHR-luciferase reporter gene (GnRHR-Luc) activity compared with
that in the GGH3 cells transfected with the promoterless
pXP2 vector.
To examine the contribution of the PKC pathway in GnRH regulation of
GnRHR gene transcriptional activity, GGH3 cells transfected
with GnRHR-pXP2 plus pCIS-lacZ or pXP2 plus
pCIS-lacZ were treated with medium alone, a metabolically
stable GnRH agonist buserelin (GnRH-A; 10-7
M), PMA (an activator of PKC; 162 nM or 100
ng/ml), or PMA (162 nM) plus GnRH-A (10-7
M) for 3 h or 6 h before harvesting. The cells
were harvested, and luciferase and ß-galactosidase were measured.
GnRH-A significantly stimulated GnRHR-Luc activity at both 3 and 6
h, with higher stimulation by 6 h (Fig. 1
). PMA also stimulated GnRHR-Luc
activity in a time-dependent manner, with a significant stimulation of
GnRHR-Luc by 6 h (Fig. 1
); however, the responses to PMA treatment
were much lower than the stimulation in response to GnRH-A. Treatment
with GnRH-A and PMA together did not cause additive stimulation of
GnRHR-Luc activity. Instead, GnRHR-Luc activity in response to
treatment with PMA and GnRH-A was lower than that in response to
treatment with GnRH-A alone (Fig. 1
). These data indicate that
activation of the PKC pathway stimulated GnRHR promoter activity,
but did not potentiate stimulation of GnRHR promoter activity by
GnRH-A.

View larger version (44K):
[in this window]
[in a new window]
|
Figure 1. Effect of a PKC activator (PMA) on GnRH
stimulation of GnRHR transcriptional activity. Forty-eight hours after
transfection of GGH3 cells with GnRHR-pXP2 plus
pCIS-lacZ or with pXP2 plus pCIS-lacZ,
the cells were incubated with medium alone, a GnRH agonist buserelin
(GnRH-A; 10-7 M), PMA (162 nM or
100 ng/ml), or PMA (162 nM) plus GnRH-A (10-7
M) for 3 or 6 h before harvesting. The cells were then
washed twice with PBS and lysed in reporter lysis buffer. Luciferase
activity in 20 µl cell lysate and ß-galactosidase activity in 30
µl cell lysate were measured. Luciferase activity was calculated as
luciferase activity/ß-galactosidase activity assayed from each well.
The luciferase activity was then normalized as the fold induction of
luciferase activity from GGH3 cells transfected with
GnRHR-pXP2 plus pCIS-lacZ divided by that from
GGH3 cells transfected with promoterless pXP2 plus
pCIS-lacZ. The data shown are the means of triplicate
determinations. Error bars show the SEM.
Significant differences at P < 0.05 between groups
are designated by different lowercase letters above the
bars.
|
|
GF 109203X is a highly selective inhibitor of PKC
,
-ßI, -ßII, -
, -
, and -
isozymes,
with an inhibitory potency that is approximately 200 times greater for
PKC than for PKA. GGH3 cells transfected with GnRHR-pXP2
plus pCIS-lacZ or with pXP2 plus pCIS-lacZ were
treated with medium alone, GnRH-A (10-7 M),
PMA (162 nM), or (Bu)2cAMP (5
mM) in presence or absence of GF 109203X (5
µM) for 6 h before harvesting. GF 109203X caused a
significant decrease in basal GnRHR-Luc activity (Fig. 2
). In addition, GF 109203X abolished
GnRH-A- or PMA-stimulated GnRHR-Luc activity (Fig. 2
). The nearly
complete blockade of PMA- or GnRH-A-stimulated GnRHR-Luc activity by
the PKC inhibitor indicated that the PKC-dependent pathway participated
in the GnRH regulation of GnRHR promoter activity. GF 109203X did not
affect (Bu)2cAMP-stimulated GnRHR-Luc activity
(Fig. 2
), thereby demonstrating the specificity of GF 109203X in
inhibiting the PKC-dependent pathway.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 2. Effect of a PKC inhibitor (GF 109203X) on GnRH
stimulation of GnRHR transcriptional activity. Forty-eight hours after
transfection of GGH3 cells with GnRHR-pXP2 plus
pCIS-lacZ or with pXP2 plus pCIS-lacZ,
the cells were incubated with medium alone, GnRH-A (10-7
M), PMA (162 nM), or (Bu)2cAMP (5
mM) in the presence or absence of GF 109203X (5
µM) for 6 h before harvesting. The cells were lysed,
and luciferase and ß-galactosidase activities were measured.
Luciferase activity was calculated as luciferase
activity/ß-galactosidase activity and then normalized as the fold
induction divided by that of pXP2. The data shown are the means of
triplicate determinations. Error bars show the
SEM. Significant differences at P <
0.05 between groups are designated by different lowercase letters
above the bars.
|
|
PMA is a pharmacological activator of most isoforms of PKC. Short term
treatment of primary cultures of pituitary cells (or other types of
cells) with PMA activates PKC activity, whereas longer term treatment
of PMA results in a depletion of PMA-sensitive isoforms of PKC,
indicated by a loss of responsiveness to exogenous PKC activators, a
loss of extractable PKC activity, and a loss of phorbol ester-binding
sites (37). To assess the effect of PKC depletion on GnRH regulation of
GnRHR promoter activity, GGH3 cells transfected with
GnRHR-pXP2 plus pCIS-lacZ or with pXP2 plus
pCIS-lacZ were pretreated with medium or PMA (1
µM) for 24 h. The cells were then stimulated with
medium alone, GnRH-A (10-7 M), PMA (162
nM), or (Bu)2cAMP (5 mM)
for 6 h before harvesting. Pretreatment with PMA resulted in a
modest, but insignificant, increase in basal GnRHR-Luc activity (Fig. 3
). Pretreatment with PMA blunted the
stimulation of GnRHR-Luc activity by GnRH-A or PMA and did not affect
the stimulation of GnRHR-Luc activity by
(Bu)2cAMP (Fig. 3
). These results further support
the view that the PKC-dependent pathway is involved in the mechanism of
GnRH activation of GnRHR transcriptional activity.

View larger version (43K):
[in this window]
[in a new window]
|
Figure 3. Effect of PKC depletion on activation of GnRHR
transcriptional activity by GnRH, PMA, and cAMP. Forty-eight hours
after transfection of GGH3 cells with GnRHR-pXP2 plus
pCIS-lacZ or with pXP2 plus pCIS-lacZ,
the cells were pretreated with medium (dimethylsulfoxide) or PMA (1
µM) for 24 h. The cells were then stimulated with
medium alone, GnRH-A (10-7 M), PMA (162
nM), or (Bu)2cAMP (5 mM) for 6
h before harvesting. The cells were lysed, and luciferase and
ß-galactosidase activities were measured. Luciferase activity was
calculated as luciferase activity/ß-galactosidase activity and then
normalized as fold induction divided by that of pXP2. The data shown
are the means of triplicate determinations. Error bars
show the SEM. Significant differences at
P < 0.05 between groups are designated by
different lowercase letters above the bars.
|
|
Involvement of Ca2+ pathway in GnRH
activation of GnRHR gene transcriptional activity
The role of Ca2+ in the regulation of GnRHR promoter
activity by the releasing hormone was assessed by preventing external
Ca2+ influx with the external Ca2+ chelator
EGTA and the Ca2+ ion channel antagonist, D600.
GGH3 cells transfected with GnRHR-pXP2 plus
pCIS-lacZ or with pXP2 plus pCIS-lacZ were
treated with medium alone, GnRH-A (10-7 M),
EGTA (2 mM), or EGTA (2 mM) plus GnRH-A
(10-7 M) for 6 h before harvesting. EGTA
did not affect basal GnRHR-Luc activity, but significantly attenuated
GnRH-A-stimulated GnRHR-Luc activity (Fig. 4A
). In the next experiment,
GGH3 cells transfected with GnRHR-pXP2 plus
pCIS-lacZ or pXP2 plus pCIS-lacZ were treated
with medium alone or GnRH-A (10-7 M) in the
absence or presence of D600 (0.01 mM or 0.1 mM)
for 6 h before harvesting. D600 was applied 30 min before GnRH-A.
Treatment with D600 resulted in a decrease in basal GnRHR-Luc activity
in a dose-dependent manner, with a significant reduction at 0.1
mM (Fig. 4B
). D600 also blocked GnRH-A-stimulated GnRHR-Luc
activity in a dose-dependent manner, with complete inhibition of
GnRH-A-stimulated GnRHR-Luc activity at 0.1 mM (Fig. 4B
).
These data suggest that the Ca2+ signal transduction
pathway is involved in the GnRH regulation of GnRHR promoter
activity.

View larger version (28K):
[in this window]
[in a new window]
|
Figure 4. Effects of Ca2+ ion chelator (A) and
Ca2+ channel antagonist (B) on GnRH activation of GnRHR
transcriptional activity. Forty-eight hours after transfection of
GGH3 cells with GnRHR-pXP2 plus pCIS-lacZ or
pXP2 plus pCIS-lacZ, the cells were incubated with
medium alone, GnRH-A (10-7 M), EGTA (2
mM), or EGTA (2 mM) plus GnRH-A
(10-7 M) for 6 h (A) or treated with
medium alone or GnRH-A (10-7 M) in the absence
or presence of D600 (0.01 and 0.1 mM) for 6 h before
harvesting (B). The cells were lysed, and luciferase and
ß-galactosidase activities were measured. Luciferase activity was
calculated as luciferase activity/ß-galactosidase activity and then
normalized as the fold induction divided by that of pXP2. The data
shown are the means of triplicate determinations. Error
bars show the SEM. Significant differences at
P < 0.05 between groups are designated by
different lowercase letters above the bars.
|
|
Involvement of the MAPK pathway in GnRH activation of GnRHR gene
transcriptional activity
Raf-1 (MAPK kinase kinase or MAPKKK) is a proximal kinase in
the mammalian ERK1/2 pathway that phosphorylates and activates MEK1 and
MEK2 (MAPK kinase or MAPKK). MEKs, in turn, mediate the activation of
ERK1 and ERK2 (18). The role of the MAPK cascade in the GnRH regulation
of GnRHR promoter activity was assessed by overexpression of
Raf-1. GGH3 cells were cotransfected with GnRHR-pXP2 or
pXP2 and different amounts of human wild-type Raf-1 expression vector
(pUSE Raf-1) for 48 h. The cells were harvested, and the
luciferase and ß-galactosidase activities were measured.
Overexpression of Raf-1 resulted in concentration-dependent inhibition
of the GnRHR-Luc activity (Fig. 5A
), with
a significant decrease in GnRHR-Luc activity at 1 and 5 µg/well Raf-1
expression vector. In the next experiment, GGH3 cells
cotransfected with GnRHR-pXP2 or pXP2 and 1 µg/well pUSE Raf-1 vector
or control vector (pcDNA3.1) were treated with GnRH-A
(10-7 M) or PKC inhibitor GF 109203X (5
µM) for 6 h before harvesting. Overexpression of
Raf-1 partially blocked GnRH-A-stimulated GnRHR-Luc activity. On the
other hand, GF 109203X inhibited basal GnRHR-Luc activity and did not
affect the inhibition of GnRHR-Luc activity by the overexpression of
Raf-1 (Fig. 5B
). These results suggested that the Raf-1-mediated MAPK
cascade is involved in the negative regulation of basal and
GnRH-stimulated GnRHR-Luc activity and that the PKC pathway is not
involved in the regulation of GnRHR-Luc activity by Raf-1.

View larger version (28K):
[in this window]
[in a new window]
|
Figure 5. Effect of overexpression of Raf-1 on basal and
GnRH-A-stimulated GnRHR transcriptional activity. A, GGH3
cells were cotransfected with GnRHR-pXP2 or pXP2 and different amounts
(0, 0.2, 1, or 5 µg) of human wild-type Raf-1 expression vector (pUSE
Raf-1) for 48 h. B, GGH3 cells cotransfected with
GnRHR-pXP2 and 1 µg/well pUSE Raf-1 vector or control vector
(pcDNA3.1) were treated with GnRH-A (10-7 M)
or PKC inhibitor GF 109203X (5 µM) for 6 h before
harvesting. The cells were then lysed, and luciferase and
ß-galactosidase activities were measured. Luciferase activity was
calculated as luciferase activity/ß-galactosidase activity and then
normalized as fold induction divided by that of pXP2. The data shown
are the means of triplicate determinations. Error bars
show the SEM. Significant differences at
P < 0.05 between groups are designated by
different lowercase letters above the bars.
|
|
PD 98059 selectively blocks the activity of MEK by inhibiting the
activation of MAPK and subsequent phosphorylation of MAPK substrates
both in vitro and in intact cells (38, 39). GGH3
cells transfected with GnRHR-pXP2 plus pCIS-lacZ or with
pXP2 plus pCIS-lacZ were treated with medium alone or GnRH-A
(10-7 M) in the absence or
presence of PD 98059 (10 or 50 µM) for 6 h before
harvesting. PD 98059 was applied 30 min before GnRH-A. Treatment with
50 µM PD 98059 significantly stimulated basal GnRHR-Luc
activity. PD 98059 also potentiated GnRH-A-stimulated GnRHR-Luc
activity (Fig. 6
).

View larger version (30K):
[in this window]
[in a new window]
|
Figure 6. Effect of MAPK kinase inhibitor on activation of
GnRHR transcriptional activity by GnRH. Forty-eight hours after
transfection of GGH3 cells with GnRHR-pXP2 plus
pCIS-lacZ or pXP2 plus pCIS-lacZ, the
cells were treated with medium alone or GnRH-A (10-7
M) in the absence or presence of PD 98059 (10 or 50
µM) for 6 h before harvesting. The cells were then
lysed, and luciferase and ß-galactosidase activities were measured.
Luciferase activity was calculated as luciferase
activity/ß-galactosidase activity and then normalized as fold
induction divided by that of pXP2. The data shown are the means of
triplicate determinations. Error bars show the
SEM. Significant differences at P <
0.05 between groups are designated by different lowercase letters
above the bars.
|
|
Kinase-deficient mutants of protein kinases, such as Raf-1, Ras,
and ERKs, have been used for interference with endogenous protein
kinases and inhibiting the activity of endogenous protein kinases (34, 40, 41). Two mutants of ERKs (K71R ERK-1 and K52R ERK-2) possess less
than 1% and less than 5% wild-type kinase activity in
vitro, respectively, and have been successfully used for
inhibition of ERK activities (25, 26, 34, 35). GGH3 cells
cotransfected with pXP2-GnRHR or pXP2 and ERK1-Mut expression vector (1
µg/well), ERK2-Mut expression vector (1 µg/well), or ERK1-Mut (0.5
µg/well) and ERK2-Mut vectors (0.5 µg/well) together were treated
with medium alone or GnRH-A (10-7 M) for
6 h before harvesting. Overexpression of ERK1-Mut or ERK2-Mut
alone did not significantly affect the basal GnRHR-Luc activity; the
combination of ERK1-Mut and ERK2-Mut significantly stimulated
GnRHR-Luc activity. On the other hand, either overexpression of
ERK1-Mut or ERK2-Mut alone or overexpression of ERK1-Mut and ERK2-Mut
together significantly increased GnRH-A-stimulated GnRHR-Luc activity.
ERK1-Mut had higher potentiation of GnRH-A-stimulated GnRHR-Luc
activity compared with ERK2-Mut, and ERK1-Mut and ERK2-Mut together
showed an additive effect of ERK1-Mut and ERK2-Mut alone (Fig. 7
). These results indicated that
inhibition of the MAPK pathway with MEK inhibitors or expression
vectors for MAPK inhibitor (kinase-deficient MAPKs) activated basal and
GnRH-A-stimulated GnRHR-Luc activities. This supports the view that the
MAPK cascade is involved in the negative regulation of basal and
GnRH-stimulated GnRHR transcriptional activity.

View larger version (32K):
[in this window]
[in a new window]
|
Figure 7. Effect of overexpression of kinase-deficient ERK
mutants on activation of GnRHR transcriptional activity by GnRH.
GGH3 cells cotransfected with pXP2-GnRHR or pXP2 and
ERK1-Mut expression vector (1 µg/well), ERK2-Mut expression vector (1
µg/well), or ERK1-Mut (0.5 µg/well) plus ERK2-Mut vectors (0.5
µg/well) were treated with medium alone or GnRH-A (10-7
M) for 6 h before harvesting. The cells were then
lysed, and luciferase and ß-galactosidase activities were measured.
Luciferase activity was calculated as luciferase
activity/ß-galactosidase activity and then normalized as the fold
induction divided by that of pXP2. The data shown are the means of
triplicate determinations. Error bars show the
SEM. Significant differences at P <
0.05 between groups are designated by different lowercase letters
above the bars.
|
|
 |
Discussion
|
|---|
The GGH3 cell line has been demonstrated to be a
useful model for study of the molecular and cellular mechanisms of GnRH
action. Recent studies from our laboratory using G protein
palmitoylation and overexpression of different G protein
-subunit
cDNAs indicated that GnRHR couples to similar G proteins
(Gq/11, Gs, and Gi) in
GGH3 cells and in pituitary primary cells, suggesting that
similar signal transduction pathways are employed to mediate GnRH
action in both cell types (17). In addition, GGH3 cells
have been used for the study of the regulation of the gonadotropin
subunit genes by GnRH. Corroborative experiments have also been
performed in these cell lines previously, which demonstrated
similarities in GnRH-mediated responses, compared with that in primary
pituitary cells, including the degree of stimulation of
, LHß, and
FSHß gene promoter activities and differential regulation of the
gonadotropin subunit gene promoter activities by GnRH (13, 42, 43). In
this study, we examined the regulation of GnRHR gene transcription by
GnRH using GGH3 transiently transfected with a luciferase
reporter gene vector (GnRHR-pXP2) containing a 1226-bp promoter
fragment of the mGnRHR gene (32).
GnRH has been shown to activate transcriptional activities of LH and
FSH subunits in part through differential use of the PKC and
Ca2+ pathways (28) or the PKC/MAPK and Ca2+
pathways (27). In addition, the frequency of Ca2+ pulses
regulates GnRHR gene expression, suggesting that GnRH-stimulated
intracellular Ca2+ signals may also be involved in
mediation of the transcriptional regulation of the GnRHR gene by GnRH
(44). In the present study, activation of PKC by PMA significantly
stimulated GnRHR-Luc activity; inhibition of PKC by GF 109203X or by
depletion of PKC blocked PMA- or GnRH-A-stimulated GnRHR-Luc activity.
Furthermore, GnRH-A-stimulated GnRHR-Luc activity was inhibited by
preventing external Ca2+ influx with Ca2+
chelator EGTA or Ca2+ ion channel antagonist, D600. These
results suggest that GnRH activates GnRHR transcriptional activity
through multiple signal transduction pathways, including PKC- and
Ca2+-dependent pathways as well as through the
cAMP-PKA-dependent pathway as previously shown. The present results
show that either GnRH-A or PMA alone significantly stimulated GnRHR-Luc
activity, although stimulation by PMA was much lower than that by
GnRH-A. However, no additional stimulation of GnRHR-Luc activity was
observed with cotreatment by GnRH-A and PMA compared with the
stimulation by GnRH-A alone. Similarly, a recent report showed that the
-subunit gene promoter activity in response to treatment with PMA
and GnRH agonist together was significantly lower than that in response
to the treatment with GnRH agonist alone (28). The mechanism for the
reduction in stimulation of GnRHR-Luc by cotreatment with GnRH-A and
PMA is unclear. A possible interpretation is that activation of PKC
isoforms by PMA could compete or down-regulate activation of the PKC
pathway by GnRH-A. Our previous study showed that GnRH activates GnRHR
gene transcription in part through the cAMP signal transduction
pathway. In the present study, use of a PKC inhibitor or depletion of
PKC did not affect (Bu)2cAMP stimulation of
GnRHR-Luc activity. However, the PKC inhibitor or depletion of PKC did
abolish PMA- or GnRH-A-stimulated GnRHR-Luc activity. In addition,
the PKC inhibitor also inhibited basal GnRHR-Luc activity. Reduction of
the basal GnRHR-Luc activity by the PKC inhibitor may conceal the
remaining GnRH-A-stimulated GnRHR-Luc activity in the presence of PKC
inhibitor, which may be caused by another signal transduction pathway
(e.g. cAMP). On the other hand, although our previous study
showed that PKC activator did not stimulate an increase in cAMP (11),
some studies showed that activation of PKC affects PKA subunit levels
in the absence of cAMP elevation, suggesting cross-talk between PKA and
PKC pathways (45).
Recent studies indicate that signaling pathways connecting GPCRs to
nuclear events regulating gene expression occur through divergent MAPK
cascades (19). MAPK was potently activated upon ligand addition by
GPCRs. The Gq/11-coupled receptor activation of MAPK
has been shown to be PKC dependent, fully PKC independent, or partially
PKC dependent (18, 19). GnRH was shown to activate MAPK activity in
T31 cells and primary cultures of pituitary cells, which probably
involved PKC and Ca2+ (22, 23, 24, 26). In addition, GnRH
activates the MAPK cascade, which, in turn, contributes to stimulation
of gonadotropin
-subunit gene promoter activity (25, 26, 27). Recent
studies revealed that GnRH regulates the transcription of LH and FSH
subunits in part through differential use of PKC/MAPK and
Ca2+ signal transduction pathways (27). In the present
study, activation of MAPK activity by overexpression of MAPK kinase
kinase (Raf-1) inhibited GnRHR-Luc activity and partially blocked
GnRH-A-stimulated GnRHR-Luc activity. In contrast, inhibition of MAPK
activity by the MAPK kinase inhibitor (PD 98059) or by overexpression
of kinase-deficient MAPKs activated basal and GnRH-A-stimulated
GnRHR-Luc activities. These unexpected results suggest that the MAPK
cascade is involved in the negative regulation of basal and
GnRH-stimulated GnRHR promoter activity. One of the mechanisms by which
the MAPK cascade mediates transduction of externally derived signals
regulating cell growth, division, and differentiation is by
phosphorylation and activation of nuclear transcription factors by MAPK
(18, 20). Phosphorylation of transcriptional factors by MAPK usually
results in increased gene expression (20). However, MAPK was shown to
phosphorylate the transrepression domain of c-Fos and c-Myb, suggesting
participation of MAPK in the repression of gene expression (46, 47).
Indeed, a recent report showed that the phosphorylation of heat shock
factor-1 by MAPK represses transcriptional activation of heat shock
gene by heat shock factor-1 (48). The mechanism of negative regulation
of GnRHR gene transcriptional activity by MAPK is unknown. It is
possible that MAPKs activated by GnRH phosphorylate transcriptional
factors, which, in turn, repress GnRHR promoter activity through their
action on the 1226-bp promoter fragment of the mGnRHR gene. Although
recent unpublished results in our laboratory showed that GnRH can
activate MAPK activity in GGH3 cells comparable to that
observed in other cell lines, the role of MAPK in regulation of GnRHR
gene transcription by GnRH is apparently needed to be confirmed using
pituitary cells or gonadotrope cell line. Studies in several other
GPCR showed that GPCR-mediated activation of PKC directly or indirectly
activates Raf kinase via a poorly understood mechanism (18, 19). In the
present study, GF 109203X inhibited basal GnRHR-activity, but did
not affect the inhibition of GnRHR-Luc activity by overexpression of
Raf-1. Although these results did not rule out the potential
involvement of PKC pathway in the activation of MAPK, they suggest that
the PKC pathway is not involved in the regulation of GnRHR gene
transcription by Raf-1.
 |
Acknowledgments
|
|---|
We are grateful to Drs. W. W. Chin, Tae H. Ji, and M.
H. Cobb for providing mouse GnRHR reporter gene vector,
pCIS-lacZ vector, and kinase-deficient ERKs expression
vectors, respectively. We thank Jo Ann Janovick for her help.
 |
Footnotes
|
|---|
1 This study was supported by NIH Grants HD-19899, RR-00163 and
HD-18185. 
Received June 11, 1998.
 |
References
|
|---|
-
Conn PM 1994 The molecular mechanism of
gonadotropin-releasing hormone action in the pituitary. In: Knobil E,
Neill JD (eds) The Physiology of Reproduction. Raven Press, New York,
pp 18151832
-
Sealfon SC, Weinstein H, Millar RP 1997 Molecular
mechanisms of ligand interaction with the gonadotropin-releasing
hormone receptor. Endocr Rev 18:180205[Abstract/Free Full Text]
-
Hawes BE, Barnes S, Conn PM 1993 Cholera toxin and
pertussis toxin provoke differential effects on luteinizing hormone
release, inositol phosphate production, and gonadotropin-releasing
hormone (GnRH) receptor binding in the gonadotrope: evidence for
multiple guanyl nucleotide binding proteins in GnRH action.
Endocrinology 132:21242130[Abstract]
-
Hsieh K-P, Martin TFJ 1992 Thyrotropin-releasing hormone and gonadotropin-releasing hormone
receptors activate phospholipase C by coupling to the guanosine
triphosphate-binding proteins Gq and G11. Mol
Endocrinol 6:16731681[Abstract]
-
Shah BH, Milligan G 1994 The
gonadotropin-releasing hormone receptor of
T31 pituitary cells
regulates cellular levels of both of the phosphoinositidase C-linked G
proteins, Gq
and G11
, equally. Mol
Pharmacol 46:17[Abstract]
-
Stanislaus D, Janovick JA, Brothers S, Conn PM 1997 Regulation of Gq/11
by the gonadotropin-releasing
hormone receptor. Mol Endocrinol 11:738746[Abstract/Free Full Text]
-
Conn PM, Janovick JA, Stanislaus D, Kuphal D, Jennes
L 1995 Molecular and cellular basis of gonadotropin-releasing
hormone action in the pituitary and central nervous system. In: Litwack
G (ed) Vitamins and Hormones. Academic Press, New York, vol 50:151214
-
Bourne GA 1988 Cyclic AMP indirectly mediates the
extracellular Ca2+-independent release of LH. Mol Cell
Endocrinol 58:155160[CrossRef][Medline]
-
Borgeat P, Chavancy G, Dupont A, Labrie F, Arimura A,
Schally AV 1972 Stimualtion of adenosine 3':5'-cyclic
monophosphate accumulation in anterior pituitary gland in vitro by
synthetic luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 69:26772681[Abstract/Free Full Text]
-
Tashjian AH JR, Yasumura Y, Levine L, Sato GH, Parker
ML 1968 Establishment of clonal strains of rat pituitary tumor
cells that secrete growth hormone. Endocrinology 82:342352[Medline]
-
Stanislaus D, Janovick JA, Jennes L, Kaiser UB, Chin WW,
Conn PM 1994 Functional and morphological characterization of four
cell lines derived from GH3 cells stably transfected with
gonadotropin-releasing hormone receptor complementary deoxyribonucleic
acid. Endocrinology 135:22202227[Abstract]
-
Kaiser UB, Conn PM, Chin WW 1997 Studies of
gonadotropin-releasing hormone (GnRH) action using GnRH
receptor-expressing pituitary cell lines. Endocr Rev 18:4670[Abstract/Free Full Text]
-
Kaiser UB, Sabbagh E, Saunders BD, Chin WW 1998 Identification of cis-acting deoxyribonucleic acid elements
that mediate gonadotropin-releasing hormone stimulation of the rat
luteinizing hormone ß-subunit gene. Endocrinology 139:24432451[Abstract/Free Full Text]
-
Janovick JA, Conn PM 1994 Gonadotropin-releasing
hormone (GnRH)-receptor coupling to inositol phosphate and prolactin
production in GH3 cells stably transfected with rat GnRH
receptor complementary deoxyribonucleic acid. Endocrinology 135:22142219[Abstract]
-
Kuphal D, Janovick JA, Kaiser UB, Chin WW, Conn PM 1994 Stable transfection of GH3 cells with rat
gonadotropin-releasing hormone receptor complementary deoxyribonucleic
acid results in expression of a receptor coupled to cyclic adenosine
3',5'-monophosphate-dependent prolactin release via a G-protein.
Endocrinology 135:315320[Abstract]
-
Lin X, Janovick JA, Brothers S, Blomenröhr M,
Bogerd J, Conn PM 1998 Addition of catfish gonadotropin-releasing
hormone (GnRH) receptor intracellualr carboxyl-terminal tail to rat
GnRH receptor alters receptor expression and regulation. Mol Endocrinol 12:161171[Abstract/Free Full Text]
-
Stanislaus D, Ponder S, Ji TH, Conn PM 1998 GnRH
receptor couples to multiple G-proteins in gonadotropes and in
GGH3 cells: evidence from palmitoylation and overexpression
of G-proteins. Biol Reprod 59:579586[Abstract/Free Full Text]
-
Van Biesen T, Luttrell LM, Hawes BE, Lefkowitz RJ 1996 Mitogenic signaling via G protein-coupled receptors. Endocr Rev 17:698714[CrossRef][Medline]
-
Gutkind JS 1998 The pathways connecting G
protein-coupled receptors to the nucleus through devergent
mitogen-activated protein kinase cascades. J Biol Chem 273:18391842[Free Full Text]
-
Campbell JS, Seger R, Graves JD, Graves LM, Jensen AM,
Krebs EG 1995 The MAP kinase cascade. Recent Prog Horm Res 50:131159
-
Ohmichi M, Sawasa T, Kanda Y, Koike K, Hirota K, Miyake
A, Saltiel AR 1994 Thyrotropin-releasing hormone stimulates MAP
kinase activity in GH3 cells by divergent pathways. J Biol Chem 269:37833788[Abstract/Free Full Text]
-
Mitchell R, Sim PJ, Leslie T, Johnson MS, Thomson
FJ 1994 Activation of MAP kinase associated with the priming
effect of LHRH. J Endocrinol 140:R15R18
-
Sim PJ, Wolbers WB, Mitchell R 1995 Activation of
MAP kinase by the LHRH receptor through a dual mechanism involving
protein kinase C and a pertussis toxin-sensitive G protein. Mol Cell
Endocrinol 112:257263[CrossRef][Medline]
-
Reiss N, Llevi LN, Shacham S, Harris D, Seger R, Naor
Z 1997 Mechanism of mitogen-activated protein kinase activation by
gonadotropin-releasing hormone in the pituitary
T31 cell line:
differential roles of Ca2+ and protein kinase C.
Endocrinology 138:16731682[Abstract/Free Full Text]
-
Roberson MS, Misra-Press A, Laurance ME, Stork PJS,
Maurer RA 1995 A role for mitogen-activated protein kinase in
mediating activation of the glycoprotein hormone a-subunit promoter by
gonadotropin-releasing hormone. Mol Cell Biol 15:35313539[Abstract]
-
Sundaresan S, Colin IM, Pestell RG, Jameson JL 1996 Stimualtion of mitogen-activated protein kinase by
gonadotropin-releasing hormone: evidence for the involvement of protein
kinase C. Endocrinology 137:304311[Abstract]
-
Weck J, Fallest PC, Pitt LK, Shupnik MA 1998 Differential gonadotropin-releasing hormone stimualtion of rat
luteinizing hormone subunit gene transcription by Ca2+
influx and mitogen-activated protein kinase-signaling pathways. Mol
Endocrinol 12:451457[Abstract/Free Full Text]
-
Saunders BD, Sabbagh E, Chin WW, Kaiser UB 1998 Differential use of signal transduction pathways in the
gonadotropin-releasing hormone-mediated regulation of gonadotropin
subunit gene expression. Endocrinology 139:18351843[Abstract/Free Full Text]
-
Bauer-Dantoin AC, Hollenberg AN, Jameson JL 1993 Dynamic regulation of gonadotropin-releasing hormone receptor mRNA
levels in the anterior pituitary gland during the rat estrous cycle.
Endocrinology 133:19111914[Abstract]
-
Brooks J, Taylor PL, Saunders PTK, Eidne KA, Struthers
WJ, McNeilly AS 1993 Cloning and sequencing of the sheep pituitary
gonadotropin-releasing hormone receptor and changes in expression of
its mRNA during the estrous cycle. Mol Cell Endocrinol 94:R23R27
-
Lin X, Conn PM 1998 Transcriptional activation of
gonadotropin-releasing hormone (GnRH) receptor gene by GnRH and cyclic
adenosine monophosphate. Endocrinology 139:38963902[Abstract/Free Full Text]
-
Albarracin CT, Kaiser, UB, Chin WW 1994 Isolation
and characterization of the 5'-flanking region of the mouse
gonadotropin-releasing hormone receptor gene. Endocrinology 135:23002306[Abstract]
-
Offermanns S, Iida-Klein A, Segre GV, Simon MI 1996 G
q family members couple parathyroid hormone
(PTH)/PTH-related peptide and calcitonin receptors to phospholipase C
in COS-7 cells. Mol Endocrinol 10:566574[Abstract]
-
Frost JA, Geppert TD, Cobb MH, Feramisco JR 1994 A
requirement for extracellular signal-regulated kinase (ERK) function in
the activation of AP-1 by Ha-Ras, phorbol 12-myristate 13-acetate, and
serum. Proc Natl Acad Sci USA 91:38443848[Abstract/Free Full Text]
-
Robbins DJ, Zhen E, Owaki H, Vanderbilt CA, Ebert D,
Geppert TD, Cobb MH 1993 Regulation and properties of
extracellular signal-regulated protein kinases 1 and 2 in
vitro. J Biol Chem 268:50975106[Abstract/Free Full Text]
-
Beck TW, Huleihel M, Gunnell M, Bonner TI, Rapp UR 1987 The complete coding sequence of the human A-raf-1
oncogene and transforming activity of a human A-raf carrying
retrovirus. Nucleic Acids Res 15:595609[Abstract/Free Full Text]
-
McArdle CA, Conn PM 1989 Use of protein kinase
C-depleted cells for investigation of the role of protein kinase C in
stimulus-response coupling in the pituitary. In: Conn PM (ed) Methods
in Enzymology. Academic Press, San Diego, vol 168:287301
-
Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel
AR 1995 A synthetic inhibitor of the mitogen-activated protein
kinase cascade. Proc Natl Acad Sci USA 92:76867689[Abstract/Free Full Text]
-
Aless DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR 1995 PD 98059 is a specific inhibitor of the activation of
mitogen-activated protein kinase in vitro and in
vivo. J Biol Chem 270:2748927494[Abstract/Free Full Text]
-
Kolch W, Heidecker G, Lloyd P, Rapp UR 1991 Raf-1
protein kinase is required for growth of induced NIH/3T3 cells. Nature 349:426428[CrossRef][Medline]
-
Pagés G, Lenormand P, LAllemain G, Chambard J-C,
Meloche S, Pouysségur J 1993 Mitogen-activated protein
kinases p42mapk and p44mapk are required for
fibroblast proliferation. Proc Natl Acad Sci USA 90:83198323[Abstract/Free Full Text]
-
Kaiser UB, Sabbagh E, Katzenellenbogen RA, Conn PM, Chin
WW 1995 A mechanism for the differential regulation of
gonadotropin subunit gene expression by gonadotropin-releasing hormone.
Proc Natl Acad Sci USA 92:1228012284[Abstract/Free Full Text]
-
Kaiser UB, Katzenellenbogen RA, Conn PM, Chin WW 1994 Evidence that signalling pathways by which thyrotropin-releasing
hormone and gonadotropin-releasing hormone act are both common and
distinct. Mol Endocrinol 8:10381048[Abstract]
-
Haisenleder DJ, Yasin M, Marshall JC 1997 Gonadotropin subunit and gonadotropin-releasing hormone receptor gene
expression are regulated by alterations in the frequency of
Ca2+ pulsatile signals. Endocrinology 138:52275230[Abstract/Free Full Text]
-
Garrel G, McArdle CA, Hemmings BA, Counis R 1997 Gonadotropin-releasing hormone and pituitary adenylate
cyclase-activating polypeptide affect levels of cyclic adenosine
3',5'-monophosphate-dependent protein kinase A (PKA) subunits in the
clonal gonadotrope alphaT31 cells: evidence for cross-talk between
PKA and protein kinase C pathways. Endocrinology 138:22592266[Abstract/Free Full Text]
-
Chen R-H, Abate C, Blenis J 1993 Phosphorylation of
the c-Fos transrepression domain by mitogen-activated protein kinase
and 90-kDa ribosomal S6 kinase. Proc Natl Acad Sci USA 90:1095210956[Abstract/Free Full Text]
-
Aziz N, Wu J, Dubendorff JW, Lipsick JS, Sturgill TW,
Bender TP 1993 c-Myb and v-Myb are differentially phosphorylated
by p42mapk in vitro. Oncogene 8:22592265[Medline]
-
Chu B, Soncin F, Price BD, Stevenson MA, Calderwood
SK 1996 Sequential phosphorylation by mitogen-activated protein
kinase and glycogen synthase kinase 3 represses transcriptional
activation by heat shock factor-1. J Biol Chem 271:3084730857[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
M. Liao, Y. Zhang, and M. L. Dufau
Protein Kinase C{alpha}-Induced Derepression of the Human Luteinizing Hormone Receptor Gene Transcription through ERK-Mediated Release of HDAC1/Sin3A Repressor Complex from Sp1 Sites
Mol. Endocrinol.,
June 1, 2008;
22(6):
1449 - 1463.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Haisenleder, L. L. Burger, H. E. Walsh, J. Stevens, K. W. Aylor, M. A. Shupnik, and J. C. Marshall
Pulsatile Gonadotropin-Releasing Hormone Stimulation of Gonadotropin Subunit Transcription in Rat Pituitaries: Evidence for the Involvement of Jun N-Terminal Kinase But Not p38
Endocrinology,
January 1, 2008;
149(1):
139 - 145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L L Burger, D J Haisenleder, A C Dalkin, and J C Marshall
Regulation of gonadotropin subunit gene transcription
J. Mol. Endocrinol.,
December 1, 2004;
33(3):
559 - 584.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ulloa-Aguirre, J. A. Janovick, A. Leanos-Miranda, and P. M. Conn
Misrouted cell surface GnRH receptors as a disease aetiology for congenital isolated hypogonadotrophic hypogonadism
Hum. Reprod. Update,
March 1, 2004;
10(2):
177 - 192.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. G. Romanelli, T. Barni, M. Maggi, M. Luconi, P. Failli, A. Pezzatini, E. Pelo, F. Torricelli, C. Crescioli, P. Ferruzzi, et al.
Expression and Function of Gonadotropin-releasing Hormone (GnRH) Receptor in Human Olfactory GnRH-secreting Neurons: AN AUTOCRINE GnRH LOOP UNDERLIES NEURONAL MIGRATION
J. Biol. Chem.,
January 2, 2004;
279(1):
117 - 126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Sadie, G. Styger, and J. Hapgood
Expression of the Mouse Gonadotropin-Releasing Hormone Receptor Gene in {alpha}T3-1 Gonadotrope Cells Is Stimulated by Cyclic 3',5'-Adenosine Monophosphate and Protein Kinase A, and Is Modulated by Steroidogenic Factor-1 and Nur77
Endocrinology,
May 1, 2003;
144(5):
1958 - 1971.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Maya-Nunez and P. Michael Conn
Cyclic Adenosine 3',5'-Monophosphate (cAMP) and cAMP Responsive Element-Binding Protein Are Involved in the Transcriptional Regulation of Gonadotropin-Releasing Hormone (GnRH) Receptor by GnRH and Mitogen-Activated Protein Kinase Signal Transduction Pathway in GGH3 Cells
Biol Reprod,
August 1, 2001;
65(2):
561 - 567.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Baratta, L.A. West, A.M. Turzillo, and T.M. Nett
Activin Modulates Differential Effects of Estradiol on Synthesis and Secretion of Follicle-Stimulating Hormone in Ovine Pituitary Cells
Biol Reprod,
February 1, 2001;
64(2):
714 - 719.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Wolfahrt, B. Kleine, H. Jarry, and W. G. Rossmanith
Endogenous regulation of the GnRH receptor by GnRH in the human placenta
Mol. Hum. Reprod.,
January 1, 2001;
7(1):
89 - 95.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Pincas, J.-N. Laverriere, and R. Counis
Pituitary Adenylate Cyclase-activating Polypeptide and Cyclic Adenosine 3',5'-Monophosphate Stimulate the Promoter Activity of the Rat Gonadotropin-releasing Hormone Receptor Gene via a Bipartite Response Element in Gonadotrope-derived Cells
J. Biol. Chem.,
June 22, 2001;
276(26):
23562 - 23571.
[Abstract]
[Full Text]
[PDF]
|
 |
|